Aurobindo initiates voluntary recall of 38 lots of ranitidine products

Aurobindo Pharma USA launched a voluntary nationwide recall of 38 lots of ranitidine products due to the detection of N-nitrosodimethylamine (NDMA) in the finished product. The impurity occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and is considered a probable human carcinogen.

Aurobindo Pharma USA launched a voluntary nationwide recall of 38 lots of ranitidine products due to the detection of N-nitrosodimethylamine (NDMA) in the finished product. The impurity occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and is considered a probable human carcinogen. The recall includes 1 lot of ranitidine tablets 150 mg and 37 lots of ranitidine capsules 150 mg, ranitidine capsules 300 mg, and ranitidine syrup 15 mg/mL. To date, the company has not received any reports of adverse events related to the recall. Individuals who are prescribed or taking any of these products should continue taking their medication, but they should contact their pharmacist or physician to discuss an alternative treatment before returning their medication. The products were distributed nationwide to Aurobindo Pharma USA and AuroHealth wholesale and distributor customers between September 28, 2018, and September 19, 2019.